Mr Jay Lefkowitz > Kirkland & Ellis LLP > New York, United States > Lawyer Profile
Kirkland & Ellis LLP Offices
601 LEXINGTON AVENUE
NEW YORK, NY 10022
NEW YORK
United States
- Firm Profile
- Go to...
Mr Jay Lefkowitz
Position
Jay Lefkowitz is a litigation partner at Kirkland and serves as lead trial and appellate counsel in shareholder disputes, securities litigation, antitrust, product liability, litigation against the FDA and False Claims Act matters. His clients include companies in the pharmaceutical, private equity, technology and telecommunications industries. He has also conducted numerous internal investigations for public companies and audit committees. In addition to winning two precedent-setting Supreme Court decisions, Jay is also a leading advocate for religious freedom and education reform, representing families and schools pro bono. Jay’s public service career includes serving as a senior White House advisor to two presidents and as U.S. Special Envoy for Human Rights in North Korea. He currently serves on Advisory Boards for numerous organizations, including Columbia Law School, NYU Alexander Hamilton Center and Barnard College, and is an adjunct professor at Columbia Law School where he teaches a seminar on Supreme Court advocacy. Jay has been named one of the “100 Most Influential Lawyers in America” by The National Law Journal and as a Law360 “MVP of the Year” six years in a row. He has also been recognized by The American Lawyer, Chambers & Partners, The Legal 500 and Benchmark Litigation.
Lawyer Rankings
United States > Healthcare > Life sciences
Regarded by clients as ‘outstanding in every aspect of their practice’, the biotechnology, pharmaceutical, and life sciences practice at Kirkland & Ellis LLP advises private equity and venture capital investors, as well as biotech and pharmaceutical companies, at varying stages of development. New York based litigator Jay Lefkowitz often acts in pharmaceutical antitrust suits, FCA and FDA related internal investigations, and product liability cases. Chicago’s ‘absolutely brilliant‘ Jim Hurst is a litigator who handles commercial, IP and patent disputes, while New York’s ‘highly experienced, highly skilled and talented‘ Patricia Carson is a life sciences litigator who focuses on patent strategy and disputes, often acting for biotech, chemical, and pharmaceutical companies.
United States > Dispute resolution > Appellate: courts of appeals / Appellate: supreme courts (states and federal)
Historically a strong player in appellate matters, Kirkland & Ellis LLP has established an impressive record of involvement in major cases at the federal courts of appeals, state appellate courts, and the US Supreme Court. In Washington DC, former Deputy Associate Attorney General John O’Quinn is noted for his expertise in IP and regulatory-related cases; he is representing Safeway in False Claims Act litigation alleging that defendants’ pharmacies misrepresented their usual and customary prices. George Hicks splits his practice between Washington DC and Dallas; he recently secured a win in the Eleventh Circuit for BP Exploration & Production in one of the first appeals addressing the ‘Back-End Litigation Option’ process established by the Deepwater Horizon medical settlement agreement. In New York, Jay Lefkowitz is recommended for his broad trial and appellate experience; he recently secured appellate victories for New Mountain Capital portfolio company, Ciox Health before the Ninth and Seventh Circuits. Washington DC-based William Burgess additionally stands out for his emphasis on patent and regulatory-related appeals. The firm saw some significant changes to its appellate practice in 2022: Paul Clement and Erin Murphy left to launch a new boutique and several attorneys followed, including Bartow Farr and Harker Rhodes.
Lawyer Rankings
- Life sciences United States > Healthcare
- Appellate: courts of appeals / Appellate: supreme courts (states and federal) United States > Dispute resolution
Top Tier Firm Rankings
- Media, technology and telecoms > Advertising and marketing: litigation
- Finance > Capital markets: high-yield debt offerings
- International Trade > CFIUS
- Antitrust > Civil litigation/class actions: defense
- Government > Government relations
- Intellectual property > Copyright
- Dispute resolution > Corporate investigations and white-collar criminal defense
- Labor and employment > Employee benefits, executive compensation and retirement plans: transactional
- Energy > Energy litigation: oil and gas
- Energy > Energy transactions: electric power
- Energy > Energy transactions: oil and gas
- Environment > Environment: transactional
- Dispute resolution > General commercial disputes
- Tax > International tax
- Dispute resolution > M&A litigation: defense
- M&A/corporate and commercial > M&A: large deals ($1bn+)
- Investment fund formation and management > Mutual/registered/exchange-traded funds
- Intellectual property > Patents: litigation (full coverage)
- M&A/corporate and commercial > Private equity buyouts: large deals ($500m+)
- Investment fund formation and management > Private equity funds (including venture capital)
- Real estate > Real estate
- Finance > Restructuring (including bankruptcy): corporate
- Dispute resolution > Securities litigation: defense
- M&A/corporate and commercial > Shareholder activism
- Media, technology and telecoms > Technology transactions
- Intellectual property > Trade secrets (litigation and non-contentious matters)
- Intellectual property > Trademarks: litigation
- Tax > US taxes: non-contentious
Firm Rankings
- Finance > Capital markets: debt offerings
- Finance > Capital markets: equity offerings
- Antitrust > Cartel
- Energy > Energy regulation: electric power
- Environment > Environment: litigation
- Media, technology and telecoms > Media and entertainment: litigation
- Antitrust > Merger control
- Media, technology and telecoms > Outsourcing
- Intellectual property > Patents: licensing
- Intellectual property > Patents: litigation (International Trade Commission)
- Dispute resolution > Product liability, mass tort and class action - defense: automotive/transport
- Dispute resolution > Product liability, mass tort and class action - defense: consumer products (including tobacco)
- Dispute resolution > Product liability, mass tort and class action - defense: pharmaceuticals and medical devices
- Dispute resolution > Product liability, mass tort and class action - defense: toxic tort
- Finance > Project finance
- Real estate > Real estate investment trusts (REITs)
- Government > State attorneys general
- Finance > Structured finance: securitization
- Tax > US taxes: contentious
- Dispute resolution > E-discovery
- Dispute resolution > Financial services litigation
- Insurance > Insurance: non-contentious
- Energy > Renewable/alternative power
- Intellectual property > Trademarks: non-contentious (including prosecution, portfolio management and licensing)
- Energy > Energy regulation: oil and gas
- Dispute resolution > Leading trial lawyers
- Healthcare > Life sciences
- Media, technology and telecoms > Media and entertainment: transactional
- Real estate > Construction (including construction litigation)
- International Trade > Customs, export controls and economic sanctions
- Dispute resolution > Leading trial lawyers
- Dispute resolution > Leading trial lawyers
- Dispute resolution > Leading trial lawyers
- Dispute resolution > Appellate: courts of appeals / Appellate: supreme courts (states and federal)
- Finance > Commercial lending
- Investment fund formation and management > Mutual/registered/exchange-traded funds